# A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

Study · id `cardio:ct-nct07216482` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07216482](<https://clinicaltrials.gov/study/NCT07216482>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07216482

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 996 participants.

## Technical summary

Registry record NCT07216482. Randomized; triple masking; primary purpose treatment. Start 2025-11-11 (actual); primary completion 2026-08-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 996 participants (enrolled count; ClinicalTrials.gov record NCT07216482, source copy `cardio:ctgov-nct07216482-2026-11-17`, retrieved 2026-11-18)
- Started: 2025-11-11 (actual) (ClinicalTrials.gov record NCT07216482, source copy `cardio:ctgov-nct07216482-2026-11-17`, retrieved 2026-11-18)
- Primary completion: 2026-08-03 (actual) (ClinicalTrials.gov record NCT07216482, source copy `cardio:ctgov-nct07216482-2026-11-17`, retrieved 2026-11-18)
- Completion: 2026-10-27 (actual) (ClinicalTrials.gov record NCT07216482, source copy `cardio:ctgov-nct07216482-2026-11-17`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Brazil; Canada; Hungary; Israel; New Zealand; Spain; Türkiye; United Kingdom (ClinicalTrials.gov record NCT07216482, source copy `cardio:ctgov-nct07216482-2026-11-17`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07216482-2026-11-17`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
- Condition: Hyperlipidemia
- Intervention (Drug): Enlicitide
- Intervention (Drug): Rosuvastatin
- Intervention (Drug): Placebo for Enlicitide
- Intervention (Drug): Placebo for Rosuvastatin
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

## Provenance

Content hash: 2421b71118aa60a1d11c3d3be75368827349750c71a7e4313bc8c1a170d99a57
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
